Trial Profile
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Ramipril (Primary) ; Temozolomide
- Indications Cognition disorders; Memory disorders
- Focus Therapeutic Use
- 20 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 03 Sep 2023 Planned primary completion date changed from 30 Jul 2024 to 31 Jul 2024.
- 11 Aug 2023 Planned primary completion date changed from 31 Jul 2024 to 30 Jul 2024.